Company Aggregate Debt: ymabs.com (YMAB)

This price chart helps assess the debt load of Y-mAbs Therapeutics (YMAB), which currently stands at 0.00. Y-mAbs Therapeutics (YMAB) generates revenue through the exclusive right to sell Danyelza for the treatment of pediatric neuroblastoma, maintaining high profitability. The business relies on sustainable development principles, implementing green packaging and minimizing carbon emissions in the logistics of its biopharmaceutical products.

This indicator aggregates all borrowed obligations to determine the level of financial leverage and solvency risk. Analyzing this trend allows for an assessment of capital management efficiency relative to operating profit. By tracking the credit load, an investor can gauge the stability of the liability structure. This is critical for Y-mAbs Therapeutics (YMAB), as patent protection and orphan drug status minimize market risks. Stable debt confirms the biotech's ability to advance its exclusive developments.